Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab-activated DC-CIK cells
- Development stage
- Unknown
- Lead developer
- Southern Medical University
- Modality
- Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
Pembrolizumab-activated DC-CIK cells represent an adoptive cell therapy combining dendritic cell-stimulated cytokine-induced killer cells (DC-CIK) that are pretreated in vitro with pembrolizumab, a monoclonal antibody targeting PD-1, before infusion to the patient. This approach aims to block PD-1-mediated inhibitory signaling in the DC-CIK cells, thereby enhancing their cytotoxic immune response and proliferation against tumor cells[1][3][4]. Mechanistically, the PD-1 blockade via pembrolizumab prevents immune exhaustion, increases immune cell infiltration at the tumor site, and promotes the production of perforin, granzyme B, and IFN-γ—key molecules for tumor cell lysis[1]. The combination has shown improved antitumor efficacy in preclinical models of hepatocellular carcinoma (HCC) as well as early-phase studies in lung and other advanced cancers[1][3][4].
- Other names
- pembrolizumab-activated DC-CIKpembrolizumab-pretreated DC-CIK cells
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab-activated DC-CIK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab-activated DC-CIK cells.